Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 4204-4209

  Shah, Unmesh ^a   Lankin, Claire M ^a   Boyle, Craig D ^a   Chackalamannil, Samuel ^a   Greenlee, William J ^a   Neustadt, Bernard R ^a   Cohen Williams, Mary E ^a   Higgins, Guy A ^a   Ng, Kwokei ^a   Varty, Geoffrey B ^a   Zhang, Hongtao ^a   Lachowicz, Jean E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

A2A; A2A antagonist; A2A receptor; A2A receptor antagonist; Adenosine; Parkinson's Disease; SCH 58261

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; ADENOSINE A2A RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARKINSON DISEASE; RAT; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ADENOSINE; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG DESIGN; HYDROGEN-ION CONCENTRATION; MODELS, CHEMICAL; PARKINSON DISEASE; PYRIMIDINES; RATS; RECEPTOR, ADENOSINE A2A; SOLUBILITY; TRIAZOLES; WATER;

RATTUS;

EID: 47149102874     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.069     Document Type: Article

References (31)

1. Shah U., Boyle C.D., Chackalamannil S., Neustadt B.R., Lindo N., Greenlee W.J., Foster C., Arik L., Zhai Y., Lachowicz J.E., Ng K., Wang S., and Monopoli A. Bioorg. Med. Chem. Lett. 18 (2008) 4199
2. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., and Williams M. Pharmacol. Rev. 46 (1994) 143
3. Ferre S., von Euler G., Johansson B., Fredholm B.B., and Fuxe K. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7238
4. 2A Receptors in Parkinson's Disease and Other CNS Disorders.
5. Zocchi C., Ongini E., Conti A., Monopoli A., Negretti A., Baraldi P.G., and Dionisotti S. J. Pharmacol. Exp. Ther. 276 (1996) 398
6. Baraldi P.G., Cacciari B., Spalluto G., Pineda de Villatoro M.J., Zocchi C., Dionisotti S., and Ongini E. J. Med. Chem. 39 (1996) 1164
7. Ongini E. Drug Dev. Res. 42 (1997) 63
8. 1 is necessary to avoid cardiac side-effects.
9. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Neurology 61 (2003) 293
10. Hauser R.A., Hubble J.P., and Truong D.D. Neurology 61 (2003) 297
11. Francis J.E., Cash W.D., Psychoyos S., Ghai G., Wenk P., Friedmann R.C., Atkins C., Warren V., Furness P., Hyun J.L., Stone G.A., Desai M., and Williams M. J. Med. Chem. 31 (1988) 1014
12. Sarges R., Howard H.R., Browne R.G., Lebel L.A., Seymour P.A., and Koe B.K. J. Med. Chem. 33 (1990) 2240
13. Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., Monopoli A., Ongini E., Varani K., and Borea P.A. J. Med. Chem. 45 (2002) 115
14. Neustadt B.R., Hao J., Lindo N., Greenlee W.J., Stamford A.W., Tulshian D., Ongini E., Hunter J., Monopoli A., Bertorelli R., Foster C., Arik L., Lachowicz J., Ng K., and Feng K.-I. Bioorg. Med. Chem. Lett. 17 (2007) 1376
15. Silverman L.S., Caldwell J.P., Greenlee W.J., Kiselgof E., Matasi J.J., Tulshian D.B., Arik L., Foster C., Bertorelli R., Monopoli A., and Ongini E. Bioorg. Med. Chem. Lett. 17 (2007) 1659
16. All compounds in this publication were isolated and tested in free base form.
17. Intermediate 2a is commercially available from Aldrich Chemical Company, Inc., Milwaukee, WI.
18. 2A receptors did not differ from affinity for the human receptor
19. Procedure described in:. Cox K.A., Dunn-Meynell K., Korfmacher W.A., Broske L., Nomeir A.A., Lin C.-C., Cayen M.N., and Barr W.H. Drug Discovery Today 4 (1999) 232 %CV values typically range from 10 to 30 in this assay (n = 2)
20. Inhibition of haloperidol-induced catalepsy is an in vivo assay used to evaluate Parkinson's drugs (>30% inhibition is considered to be active in this assay)
21. Mandhane S.N., Chopde C.T., and Ghosh A. Eur. J. Pharmacol. 328 (1997) 135
22. Procedure described in:. Matasi J.J., Caldwell J.P., Zhang H., Fawzi A., Cohen-Williams M.E., Varty G.B., and Tulshian D.B. Bioorg. Med. Chem. Lett. 15 (2005) 3670
23. The nephelometric (light scattering) method was used to determine the kinetic solubility of compounds. The test compound (1.0 mg) was dissolved in DMSO at 25 mM.A serial dilution into DMSO was performed and 3 μl of the compound in DMSO at various concentrations was added to the buffer (10 mM phosphate, pH 7.4). Presence of precipitate was detected by nephelometry. Solubility was defined as the highest concentration of material that did not scatter light. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 46 (2001) 3
24. Tetrahydroisoquinolines 2i, 2j, and 10 were synthesized as described in:. Sall D.J., and Grunewald G.L. J. Med. Chem. 30 (1987) 2208 Intermediates 2e-2g are commercially available from Acros Organics, Morris Plains, NJ
25. Benzazepine 2m was synthesized as described in:. Pecherer B., Sunbury R.C., and Brossi A. J. Heterocycl. Chem. 8 (1971) 779 The unsubstituted intermediate 2l is commercially available from Scientific Exchange, Inc., Center Ossipee, NH
26. The synthesis of intermediate 2r is reported in the following reference:. Shiozawa A., Ichikawa Y.-I., Ishikawa M., Kogo Y., Kurashige S., Miyazaki H., Yamanaka H., and Sakamoto T. Chem. Pharm. Bull. 32 (1984) 995
27. The synthesis of intermediate 2s is reported in the following reference:. Shiozawa A., Ichikawa Y.-I., Komuro C., Kurashige S., Miyazaki H., Yamanaka H., and Sakamoto T. Chem. Pharm. Bull. 32 (1984) 2522
28. Intermediate 13 was synthesized as described in:. Matsumura E., Ariga M., and Tohda Y. Bull. Chem. Soc. Jpn. 39 (1979) 2413
29. Cyclization of 13 to form a 3-nitrotetrahydronaphthyridine is reported in:. Harling J.D., Harrington F.P., and Thompson M. Synth. Commun. 31 (2001) 787
30. The synthesis of intermediate 2w is reported in:. Fukui H., Inoguchi K., and Nakano J. Heterocycles 56 (2002) 257
31. The synthesis of intermediate 2x is described in: Ashton, W. T.; Caldwell, C. G.; Duffy, J. L.; Mathvink, R. J.; Wang, L.; Weber, A. E. WO Patent 2004069162, 2004.